+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East and Africa Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • PDF Icon


  • 90 Pages
  • April 2023
  • Region: Africa, Middle East
  • Mordor Intelligence
  • ID: 5764773
UP TO OFF until Mar 31st 2024
The Middle East and Africa kidney cancer therapeutics and diagnostics market is projected to grow at a CAGR of 5.2% over the forecast period.

The COVID-19 pandemic affected healthcare systems and resulted in the interruption of general care in many healthcare facilities. This situation exposed patients with cancer to significant risks. According to the study published in the Journal of Clinical Oncology in June 2022, patients with cancer were reported to be a vulnerable population that suffered from SARS-CoV-2 infection and the pandemic's impact on healthcare systems during the COVID-19 pandemic. There were significant negative implications for patients with kidney cancer when medical attention was diverted exclusively to COVID-19 patients. Thus, during the COVID-19 pandemic, the kidney cancer therapeutics and diagnostics market was severely impacted. Since restrictions were removed, the market has been recovering strongly. Over the past two years, a rise in hospital visits, the reopening of clinics, and the diagnostics lab have been driving the market recovery.

The market expected show rapid growth due to the rising number of kidney cancer cases in the region and the increasing R&D expenditure of pharmaceutical companies. Excessive smoking, an increase in obesity levels, and increased intake of alcohol are some of the causes of kidney cancer in the region. According to the study published in Urology Annals in March 2022, in Saudi Arabia, kidney tumor incidence and mortality account for 3.4% and 2.4% of the population, respectively, with males and the elderly being more affected. Renal cell carcinoma accounts for approximately 85% of all kidney tumors (RCC). Though the prevalence of kidney cancer cases in the region is less compared to the other region of the world, the incidence is still increasing during the recent years, due to lifestyle changes.

Moreover, various initiatives taken by the market players are likely to support the growth of the market. For instance, in March 2022, in the United Arab Emirates AstraZeneca pharmaceutical hosted a worldwide summit to help change the trajectory of cancer diagnosis, treatment, and cure.

Factors such as rising burden of kidney cancer and product launches by market players are expected to contribute to market growth over the forecast period in the Middle East and African region. However, the high cost associated with the treatment may restrain the market growth.

MEA Kidney Cancer Therapeutics & Diagnostics Market Trends

Renal Cancer Carcinoma is Expected to Hold a Major Share in the Studied Market Over The Forecast Period.

Renal cell cancer (also known as kidney cancer or renal cell adenocarcinoma) is a condition in which malignant (cancer) cells are detected in the lining of the kidney's tubules (very small tubes). The different treatment options for people with RCC include surgery, immunotherapy, and targeted therapy.

Targeted therapy targets the changes in cancer cells that help them grow, divide, and spread. Some targeted therapies to treat clear cell renal carcinoma include using cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib. According to GLOBOCAN 2020, the incidence of kidney cancer cases in Egypt has been recorded at 2,208, while five-year prevalence cases were 5,717. According to the same source, Nigeria's number of kidney cancer cases was 2,608 in 2020, with five-year prevalence cases of 5,472. The growing incidence of the early diagnosis and treatment of these cancers is boosting the segment's growth.

According to the study published in Cancer Management Research in February 2022, the reported prevalence of RCC was 0.7%. The most prevalent histological type was clear cell RCC (67.8%), followed by papillary RCC (15.6%). Thus, RCC is the highly prevalent histopathological condition in kidney cancer, and the growing burden of it is projected to boost the segment growth.

South Africa is Expected to Dominate the Studied Market Over the Forecast Period

South Africa dominates the kidney cancer therapeutics and diagnostics market. The major factor driving the growth is the increasing number of kidney cancer cases and product launches by the key market players. Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of an aging population, are expected to lead to the growth of the market in the forecast period. For instance, as per the GLOBOCAN 2020, the estimated number of new kidney and renal pelvis cancer cases, including both sexes and all ages in 2020 was 1.33 thousand million in South Africa and the number is estimated to reach 2.07 thousand million by the year 2040. Therefore, such a high burden of kidney cancer in South Africa is anticipated to fuel the demand for cancer therapy, thereby fueling market growth.

Furthermore, various strategies adopted by the key market players such as product launches, mergers and acquisitions, and partnerships accelerate the growth of the market. For instance, in March 2021, Icon Oncology and Mediclinic Southern Africa reported one of the first-in-South Africa partnership that aims to deliver seamless one-stop oncology services at a new flagship treatment facility based at Mediclinic Constantiaberg in Cape Town. The establishment of such facilities is expected to increase accessibility to treatment and diagnosis and thus expected to drive the growth of the market in the country.

Thus, factors such as growing burden of kidney cancer and strategic initiatives by key market players is expected to market growth over the forecast period in South Africa.

MEA Kidney Cancer Therapeutics & Diagnostics Market Competitor Analysis

The Middle East and Africa kidney cancer therapeutics & diagnostics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Abbott Laboratories, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Amgen Inc., and Merck & Co. Inc.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Kidney Cancer Cases
4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value USD million)
5.1 By Cancer Type
5.1.1 Renal Cancer Carcinoma?
5.1.2 Clear Cell Renal Cell Carcinoma
5.1.3 Papillary Renal Cell Carcinoma?
5.1.4 Other Kidney Cancers
5.2 By Component
5.2.1 Drugs Therapeutic Class Pharmacologic Class
5.2.2 Diagnostics Biopsy Imaging Tests Others
5.3 Geography
5.3.1 Saudi Arabia
5.3.2 United Arab Emirates
5.3.3 South Africa
5.3.4 Rest of Middle East and Africa
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bayer AG
6.1.3 Bristol Myers Squibb Company
6.1.4 F. Hoffmann-La Roche
6.1.5 Amgen Inc.
6.1.6 Merck & Co. Inc.
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Illumina Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Bayer AG
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche
  • Amgen Inc.
  • Merck & Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.